payday loans
wholesale jerseys
Skip to content

Accueil
L'essentiel de la littérature réçente en Pneumologie

Dans cette rubrique on vous propose une revue de la littérature à travers une sélection d'abstracts d'articles originaux.
On essaiera de vous tenir informé des dernières nouveautés de recherche en matière de Pneumologie. On ne vous fournit que le résumé de l'article et le lien correspondant, pour accéder à l'article en full text vous devez être inscrits à la revue correspondante.
Cliquez ici pour consulter la liste des revues de Pneumologie disponibles en libre accès.



Smoking and the Outcome of Infection Imprimer Envoyer
Lundi, 29 Novembre 2010 07:02

Smoking has substantial local and systemic adverse effects on the immune system, respiratory tract and skin and soft tissues. Smokers are at increased risk of invasive pneumococcal disease, pneumonia, periodontitis, surgical infections, tuberculosis, influenza and meningococcal disease.

The results of several studies indicate that smokers with periodontitis or tuberculosis suffer more‐severe disease. Data on the impact of smoking in sepsis and pneumonia are controversial and limited, and systematic data regarding the outcome of the majority of infections in smokers are scarce. Abundant data indicate that children exposed to environmental tobacco smoke (ETS) suffer from more‐severe infections.

However, information regarding the effects of ETS on the outcome of infections in adul...

Lire la suite...
 
Pulmonary Diseases and the Liver Imprimer Envoyer
Lundi, 29 Novembre 2010 07:02

Chronic liver disease is associated with many pulmonary complications.

Several, including hepatopulmonary syndrome, portopulmonary hypertension, and hepatic hydrothorax have been extensively reviewed. However, hepatobiliary manifestations of primary pulmonary diseases have received less attention. This review focuses on hepatobiliary complications of respiratory failure, cystic fibrosis, α-1 antitrypsin deficiency, sarcoidosis, and tuberculosis.

Lire la suite...
 
Long-acting Beta-agonists in the Management of Chronic Obstructive Pulmonary Disease: Current and Future Agents Imprimer Envoyer
Lundi, 29 Novembre 2010 07:02

Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and debilitating symptoms.

For patients with moderate-to-severe COPD, longacting bronchodilators are the mainstay of therapy; as symptoms progress, guidelines recommend combining bronchodilators from different classes to improve efficacy. Inhaled long-acting β2-agonists (LABAs) have been licensed for the treatment of COPD since the late 1990s and include formoterol and salmeterol. They improve lung function, symptoms of breathlessness and exercise limitation, health-related quality of life, and may reduce the rate of exacerbations, although not all patients achieve clinically meaningful improvements in symptoms or health related quality of life. In addition, LABAs have an acceptable safety profile, and are not associated with an increased risk of respiratory mortality, although adverse effects such as palpitations and tremor may limit the dose that can be tolerated...

Lire la suite...
 
<< Début < Précédent 3331 3332 3333 3334 3335 3336 3337 Suivant > Fin >>

Page 3334 sur 3337

find-us-on-facebook-2

United4LungHealth

image001

World Allergy Week 2017 The Agony of Hives

WCOPDday2017



PubMed Logo
Word

 To: 

Langtolang Dictionary

CNP2017

50x50_firefoxsafari_iconGchrome

Notre site est optimisé pour les Navigateurs suivants : Firefox, Safari et Google Chrome. Cliquez sur l'un des logos ci-dessus pour le télécharger et l'installer gratuitement.

Tabac

Accueil Top